Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...
Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...
From 1,085 citations identified, 48 studies with 15,368 men with mCRPC met inclusion criteria. Most studies were retrospective cohorts (n = 39) from Europe (n = 22) and North America (n = 18), with ...
SAN FRANCISCO -- Patients with high-risk prostate cancer had a significantly lower incidence of distant metastasis when ...
Barry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.
Fantastic fundraising” efforts were hailed when NHS staff joined campaigners to celebrate the success of an appeal which will revolutionise ...
Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...
Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...
The primary study objective was to evaluate the prognostic value of post-therapeutic SPECT by RECIP 1.0 for overall survival.
The Elekta Unity MR-LINAC system combines MRI imaging with radiation therapy to target cancerous cells with pinpoint ...
There could be new hope on for kidney cancer patients. Researchers announced early results of an anti-tumor vaccine for patients with stage 3 or 4 kidney cancer, who face high recurrence risk.
The Decipher Bladder Genomic Subtyping Classifier found that patients with luminal tumors may have less aggressive disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results